Lori Brisbin, MS, MLS

Liquid biopsy and at-home phlebotomy are closing precision medicine access gaps nationwide, though tissue remains the gold standard.

This final segment summarizes key themes and future directions in the management of hormone receptor–positive, HER2-negative breast cancer.

This segment explores the emerging use of circulating tumor DNA trends, including variant allele frequency, as a potential tool to guide monitoring in hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores the emerging and controversial role of circulating tumor DNA in guiding treatment decisions in hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores the challenges of differentiating among multiple oral selective estrogen receptor degraders as they become available for hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores emerging challenges in treatment sequencing for hormone receptor–positive, HER2-negative metastatic breast cancer as oral selective estrogen receptor degraders move into earlier lines of therapy.

This segment explores the evolving role of oral selective estrogen receptor degraders in early-stage hormone receptor–positive, HER2-negative breast cancer and their potential impact on treatment paradigms.

This segment explores how ESR1 mutation testing may be integrated into clinical workflows for hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores practical considerations for implementing ESR1 mutation testing in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on testing strategy, frequency, and system-level constraints.

This segment explores increasing interest from both patients and clinicians in ctDNA testing and emerging targeted therapies in hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores patient perspectives and acceptance of biomarker-driven treatment strategies in hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores the growing role of genomic testing and multidisciplinary coordination in the management of hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores deeper clinical interpretations of the SERENA-6 trial, particularly focusing on circulating tumor DNA dynamics and their relevance in hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment focuses on the clinical implications of the SERENA-6 trial and its evaluation of circulating tumor DNA–guided treatment switching in hormone receptor–positive, HER2-negative metastatic breast cancer. Dr. Adam Brufsky introduces the trial within the context of ongoing regulatory and clinical debate regarding biomarker-driven intervention prior to radiographic progression.

This segment examines real-world access and reimbursement considerations influencing the use of oral selective estrogen receptor degraders in hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.